Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.

Leukemia & lymphoma - 1 May 2024

Tabari Ehsan, Lovejoy Alexander F, Lin Hai, Bolen Christopher R, Lor Saelee Seng, Lefkowitz Joshua P, Kurtz David M, Bottos Alessia, Nielsen Tina G, Parreira Joana M, Luong Khai T

Abstract excerpt

Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a next-generation sequencing (NGS)-based method to assess a range of potential prognostic indicators, and evaluated it using pretreatment plasma samples from 310 patients with previously untreated DLBCL from the GOYA trial (NCT01287741). Variant calls and DLBCL subtyping...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prognosis

Share to Tumor Burden

Source

Identifiers

PMID: 38337191
DOI: 10.1080/10428194.2024.2301924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.PMID 38337191Read ↗

High-risk subgroup and associated genes identified by next generation sequencing in diffuse large B cell lymphoma.Semantic proximity Read ↗

Next-generation prognostic assessment for diffuse large B-cell lymphoma.Semantic proximity Read ↗

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLSemantic proximity Read ↗

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Semantic proximity Read ↗

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?Semantic proximity Read ↗

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.Semantic proximity Read ↗

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.